A New Strategy to Preserve and Assess Oxygen Consumption in Murine Tissues.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Dec 2021
Historique:
received: 08 11 2021
revised: 13 12 2021
accepted: 17 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 1 2 2022
Statut: epublish

Résumé

Mitochondrial dysfunctions are implicated in several pathologies, such as metabolic, cardiovascular, respiratory, and neurological diseases, as well as in cancer and aging. These metabolic alterations are usually assessed in human or murine samples by mitochondrial respiratory chain enzymatic assays, by measuring the oxygen consumption of intact mitochondria isolated from tissues, or from cells obtained after physical or enzymatic disruption of the tissues. However, these methodologies do not maintain tissue multicellular organization and cell-cell interactions, known to influence mitochondrial metabolism. Here, we develop an optimal model to measure mitochondrial oxygen consumption in heart and lung tissue samples using the XF24 Extracellular Flux Analyzer (Seahorse) and discuss the advantages and limitations of this technological approach. Our results demonstrate that tissue organization, as well as mitochondrial ultrastructure and respiratory function, are preserved in heart and lung tissues freshly processed or after overnight conservation at 4 °C. Using this method, we confirmed the repeatedly reported obesity-associated mitochondrial dysfunction in the heart and extended it to the lungs. We set up and validated a new strategy to optimally assess mitochondrial function in murine tissues. As such, this method is of great potential interest for monitoring mitochondrial function in cohort samples.

Identifiants

pubmed: 35008535
pii: ijms23010109
doi: 10.3390/ijms23010109
pmc: PMC8745047
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Protoc. 2017 Dec;12(12):2623-2639
pubmed: 29189769
Methods Mol Biol. 2018;1732:289-305
pubmed: 29480483
Nat Protoc. 2012 May 31;7(6):1235-46
pubmed: 22653162
J Cell Biochem. 2018 Nov;119(11):9602
pubmed: 30171706
J Biomed Opt. 2011 Mar;16(3):037005
pubmed: 21456878
Metabolism. 2015 Aug;64(8):917-25
pubmed: 25982698
Nat Protoc. 2008;3(6):965-76
pubmed: 18536644
PLoS One. 2011 Mar 28;6(3):e18317
pubmed: 21512578
Trends Mol Med. 2021 Feb;27(2):185-198
pubmed: 32952044
J Exp Biol. 1998 Apr;201(Pt 8):1129-39
pubmed: 9510525
J Gerontol A Biol Sci Med Sci. 2012 Oct;67(10):1022-35
pubmed: 22459622
Oncotarget. 2016 Jun 28;7(26):39473-39485
pubmed: 27250023
Nat Med. 2014 Jan;20(1):54-61
pubmed: 24336249
J Vis Exp. 2011 Feb 28;(48):
pubmed: 21403632
Mitochondrion. 2018 Nov;43:25-29
pubmed: 29944924
J Clin Invest. 2018 Dec 3;128(12):5191-5194
pubmed: 30371508
Ann N Y Acad Sci. 2010 Feb;1188:191-8
pubmed: 20201903
Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1047-58
pubmed: 21386058
Ann Transl Med. 2018 Jun;6(12):256
pubmed: 30069458
Methods Enzymol. 2009;457:373-93
pubmed: 19426879
Nat Protoc. 2007;2(2):287-95
pubmed: 17406588
PLoS One. 2016 Aug 02;11(8):e0160407
pubmed: 27483441
Anesth Analg. 2015 Feb;120(2):320-8
pubmed: 25427286
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
J Clin Invest. 2019 Jan 2;129(1):34-45
pubmed: 30601141
J Clin Invest. 2016 Mar 1;126(3):809-20
pubmed: 26928034
Nat Protoc. 2012 May 10;7(6):1068-85
pubmed: 22576106

Auteurs

Jerome Kluza (J)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut pour la Recherche sur le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Victoriane Peugnet (V)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France.

Blanche Daunou (B)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

William Laine (W)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut pour la Recherche sur le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Gwenola Kervoaze (G)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Gaëlle Rémy (G)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Anne Loyens (A)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut pour la Recherche sur le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Patrice Maboudou (P)

Centre de Bio-Pathologie, CHRU Lille, 59000 Lille, France.

Quentin Fovez (Q)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut pour la Recherche sur le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Corinne Grangette (C)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Isabelle Wolowczuk (I)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Philippe Gosset (P)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Guillaume Garçon (G)

Univ. Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPacts de l'Environnement Chimique sur la Santé (IMPECS), 59000 Lille, France.

Philippe Marchetti (P)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut pour la Recherche sur le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Florence Pinet (F)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France.

Muriel Pichavant (M)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, 59000 Lille, France.

Emilie Dubois-Deruy (E)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, 59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH